Segments - Hereditary Testing Market by Disease Types (Hereditary Cancer Testing [Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer, and Others] and Hereditary Non-cancer Testing [Genetic Tests {Cardiac Diseases, Rare Diseases, and Others}, Newborn Genetic Screening, Preimplantation Genetic Diagnosis & Screening, and Non-invasive Prenatal Testing & Carrier Screening Tests]) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The Hereditary Testing Market size was USD 6.63 Billion in 2022 and is likely to reach USD USD 13.7 Billion by 2031, expanding at a CAGR of 8.4% during 2023–2031. The growth of the market is attributed to the growth of reproductive genetic health sector.
Hereditary testing, also simply known as genetic testing, refers to a type of laboratory testing that examines and analyzes a blood sample or any swab sample to identify genetic differences linked to hereditary or genetic disorder. This testing is widely used to determine if a person is at high risk for a genetic disorder that runs in their family such as hereditary cancer syndromes or neurological disorder.
This genetic testing can be conducted at any stage of life, from pregnancy to adulthood. There are several types of genetic testing and no single genetic test that can detect all types of genetic disorders. Different genetic testing is done that is unique to patient, depending on patient’s medical and family history, as well as the kind of ailment.
The genetic testing can be classified into single gene testing, panel testing, and Large-scale genetic or genomic testing. Large-scale genetic or genomic testing is further bifurcated into exome sequencing and genome testing. Doctors prescribe exome and genome sequencing for patients with complicated medical histories.
Genomic testing on a large scale is also utilized in research to understand more about the genetic origins of diseases. Large-scale genetic tests can provide results that have nothing to do with why the test was requested in the first place. Genetic testing, in general, pose no physical danger. Blood and cheek swab testing are almost risk-free. A genetic test may or may not yield useful information on the gene in issue in various situations.
Everyone's genes are different and these differences do not always have an impact on your health. However, distinguishing between a disease-causing gene and a harmless gene variant might be challenging at times. Variants of uncertain significance are the term given to these changes. Follow-up testing or periodic assessments of the gene throughout time may be required in these cases.
The report on the global hereditary testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Hereditary Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Disease Types (Hereditary Cancer Testing [Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer, and Others] and Hereditary Non-cancer Testing [Genetic Tests {Cardiac Diseases, Rare Diseases, and Others}, Newborn Genetic Screening, Preimplantation Genetic Diagnosis & Screening, and Non-invasive Prenatal Testing & Carrier Screening Tests]) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Inc.; CooperSurgical, Inc.; Agilent Technologies, Inc.; and Thermo Fisher Scientific, Inc. |
Based on disease types, the global hereditary testing market is bifurcated into hereditary cancer testing and hereditary non-cancer testing. The hereditary cancer testing is further divided into lung cancer, breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, uterine cancer, pancreatic cancer, and others.
While the hereditary non-cancer testing segment is further segmented into genetic tests, newborn genetic screening, preimplantation genetic diagnosis & screening, and non-invasive prenatal testing (NIPT) & carrier screening tests. Meanwhile, the genetic tests segment is further sub-segmented into cardiac diseases, rare diseases, and others.
The hereditary cancer testing segment is likely to dominate the market in the coming years owing to rising number of cancer cases globally and rapid development of new technology for cancer diagnostic devices On the other hand, the Lung cancer segment is anticipated to expand at a rapid pace during the forecast period as majority of lung cancer are not related to inherited genetic mutations.
Similarly, the Human Papillomavirus (HPV) causes most cervical cancer cases, rather than genetic alterations. Furthermore, lack of adequate evidence on cervical cancer heredity is expected to boost the research activities in this segment.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is expected to hold a key share of the global hereditary testing market with a large revenue share during the forecast period. The growth of the segment is attributed to presence of key players that are providing innovative and effective genetic tests, the widespread use of advanced treatments, and government recommendations to ensure the quality of hereditary testing services.
On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rising awareness and improvements in healthcare facilities. Furthermore, increasing demand newborn testing in the region is also expected to drive the market growth in this region.
The global hereditary testing market has been segmented on the basis of
Some of the major players competing in the global hereditary testing market are Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Inc.; CooperSurgical, Inc.; Agilent Technologies, Inc.; and Thermo Fisher Scientific, Inc.
Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
For example, in September 2019, Blueprint Genetics, a Finnish firm, patenered with ARCHIMEDlife, a rare disease diagnostics firm, to provide biochemical testing for rare disorders in North America. Both companies intended to expand their genetic illness testing services through this collaboration in order to better serve their consumers.